Los Angeles Capital Management LLC Sells 64,393 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Los Angeles Capital Management LLC trimmed its stake in Sana Biotechnology, Inc. (NASDAQ:SANA) by 47.8% in the 1st quarter, Holdings Channel.com reports. The firm owned 70,245 shares of the company’s stock after selling 64,393 shares during the period. Los Angeles Capital Management LLC’s holdings in Sana Biotechnology were worth $702,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Victory Capital Management Inc. bought a new stake in Sana Biotechnology in the fourth quarter worth $54,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Sana Biotechnology by 42.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,257 shares of the company’s stock worth $66,000 after purchasing an additional 4,815 shares during the period. Simplex Trading LLC grew its holdings in Sana Biotechnology by 31.3% during the 4th quarter. Simplex Trading LLC now owns 18,080 shares of the company’s stock valued at $73,000 after purchasing an additional 4,313 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Sana Biotechnology by 351.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,800 shares of the company’s stock worth $93,000 after purchasing an additional 17,753 shares during the period. Finally, E Fund Management Co. Ltd. lifted its stake in Sana Biotechnology by 40.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 23,361 shares of the company’s stock worth $95,000 after purchasing an additional 6,673 shares during the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Trading Up 0.5 %

Shares of NASDAQ SANA opened at $5.54 on Tuesday. Sana Biotechnology, Inc. has a 52-week low of $2.74 and a 52-week high of $12.00. The stock has a 50 day moving average price of $7.95 and a 200 day moving average price of $7.35.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). Research analysts predict that Sana Biotechnology, Inc. will post -1.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on SANA shares. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Sana Biotechnology in a research note on Thursday, May 9th. JMP Securities lifted their target price on Sana Biotechnology from $8.00 to $15.00 and gave the stock a “market outperform” rating in a research report on Friday, March 1st.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.